MedTrace Logo

Apatinib as First -Line Treatment for Advanced Esophagus Cancer

NCT03542422 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-06-14

No results posted yet for this study

Summary

An Exploratory study of Amapinib for patients with advanced esophagus cancer .

Conditions

  • Advanced Esophagus Cancer

Interventions

DRUG

Apatinib

Metastasis after primary treatment : Apatinib + yew + platinum. Local recurrence after previous surgery/radiotherapy: Apatinib alone or in combination with platinum-based chemotherapy.

Sponsors & Collaborators

  • Affiliated Hospital of North Sichuan Medical College

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-30
Primary Completion
2018-12-31
Completion
2019-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03542422 on ClinicalTrials.gov